Literature DB >> 34333197

TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.

Haibei Xin1, Cunzhen Zhang1, Zhiwen Ding1, Minfeng Zhang1, Guanghui Ding1, Nan Li2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34333197     DOI： 10.1016/j.clinre.2021.101777

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN： 2210-7401            Impact factor:   2.947


× No keyword cloud information.
  2 in total

1.  Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.

Authors:  Yanqiao Ren; Yusheng Guo; Lei Chen; Tao Sun; Weihua Zhang; Bo Sun; Licheng Zhu; Fu Xiong; Chuansheng Zheng
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

Review 2.  Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.

Authors:  Qimeng Gao; Imran J Anwar; Nader Abraham; Andrew S Barbas
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.